CTCs, CTC clusters and CTC-WBC clusters harvested using Parsortix were more numerous and more aggressive in initiating metastasis during sleep
Angle PLC (AIM:AGL) Spread of breast cancer accelerates during sleep
Angle PLC (AIM:AGL) Molecular characterisation of CTCs
PARSORTIX ENABLES MOLECULAR CHARACTERISATION OF CTCS ISOLATED FROM FROZEN SAMPLES IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND SARCOMA
Immupharma PLC (AIM:IMM) Finals results for y/e 31 December 2021
ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2021 (the
Immupharma PLC (AIM:IMM) UPDATE on P140 (LUPUZORT) clinical progress
Data confirms positive readout from P140 PK study
MiNK the Agenus Cell Therapy spinoff makes its mark on Wall Street with $40M IPO
MiNK Therapeutics secured its Nasdaq spot Friday with a $40 million initial public offer. This was to allow MiNK Therapeutics to move its lead candidate through phase I trials in
NASDAQ:TLSA | LSE:TILS: Foralumab Now in CAR T
On September 2nd, Tiziana Life Sciences PLC (NASDAQ:TLSA) (LSE:TILS) announced an exclusive licensing agreement with Precision BioSciences (NASDAQ:DTIL) for the exploration and development of foralumab as a lymphodepletion agent to
Tiziana Life Science (TILS.L) TLSA to Host Call to Discuss Exclusive License
Tiziana to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
Tiziana Life Sciences plc (TILS.L) Posting of Scheme Document and Notice of Meetings
London/New York, 3 September 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Old Tiziana”) a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases
Avacta Group PLC (AVCT.L) Appointment of Chief Scientific Officer
Appointment of Dr Fiona McLaughlin as Chief Scientific Officer of Avacta’s Therapeutics Division
Tiziana Life Science (TILS.L) License Agreement to Evaluate Foralumab with CAR T
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
Tiziana Life Sciences plc (TILS.L) TiLS files scheme for a corporate reorganisation
London/New York, August 20, 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Old Tiziana”) a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases
